Hemab Therapeutics, a late stage clinical biotechnology company developing novel prophylactic therapeutics for serious, underserved coagulation disorders, today announced that the U.S. Food and Drug ...

Sutacimig is an investigational bispecific antibody designed to bind to endogenous factor VIIa and localize it to activated platelets, thereby promoting thrombin and fibrin formation.

Add Yahoo as a preferred source to see more of our stories on Google. The creation of this new approach to stopping bleeding has unparalleled potential if moved forward in the medical industry, and ...

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...